The Profit Margin Double Standard That Needs To Change

By Maria Ladd

Pharmaceutical companies are expected to produce healthy margins — yet research sites are questioned for seeking the same. Why is it problematic, and difficult, too, for sites to achieve a sustaining profit margin? It’s time to examine what this disparity costs the industry.

Two organizations sit across a contract negotiation table. One is a publicly traded pharmaceutical company. Its gross profit margin (revenue minus manufacturing costs) routinely runs between 70 and 80 percent. Its net income margin, after R&D and operating expenses, is lower but still nearly double the average of other large public companies. The industry defends that remainder as the fuel for future innovation. The other organization at the table is a clinical research site trying to justify why it needs $85 per hour for a study coordinator's time.

One of those organizations will be asked to defend its margin — and it will not be the pharmaceutical company.

A Tale Of Two Margins

The pharmaceutical industry operates within a well-understood and largely accepted framework of commercial return. Drug development is expensive, timelines are long, and failure rates are high. Profit margins exist not only to reward shareholders but to fund the research pipeline. That argument is broadly accepted across industry, media, and policy circles, even when individual pricing decisions are scrutinized.

Research sites occupy a fundamentally different position. Often born from clinical practices, academic institutions, or mission-driven healthcare organizations, sites carry an implicit association with patient care and scientific service. On the opposite end of the negotiating table, that association has been gradually weaponized in budget conversations to suggest that financial sustainability should not be a primary concern.

The result is a budget culture where sponsor and CRO representatives routinely push back on site line items. Study coordinator hours are questioned, principal investigator oversight fees are challenged, and start-up and closeout costs are trimmed. Meanwhile, sponsor program management fees, CRO pass-throughs, and overhead allocations flow through without the same level of examination.

What This Looks Like In Practice

The double standard manifests in several recognizable ways across the site-sponsor-CRO relationship.

The Rate Card Resistance

When a research site develops a transparent, defensible rate card built on actual labor costs, overhead allocation, and reasonable margin, sponsors and CROs sometimes receive it as an act of aggression rather than a professional business practice. Yet the same organizations maintain their own internal rate structures, often far less transparent, that are never submitted for the other party's approval. A site is routinely asked to justify what it charges per coordinator hour. A CRO's billable rate for equivalent staff time (carrying its own overhead, margin, and markup) is a line item, too, but it is accepted as standard. The difference is not the existence of margin. It is whose margin gets questioned.

The Overhead Interrogation

Sites are expected to justify costs that sponsors and CROs treat as given. A coordinator training line gets flagged as out of scope. A CRO's project management fees and a sponsor's internal clinical operations costs face the same budget process but their right to earn a margin on top is never in dispute.

That gap is the point. It is not that CROs and sponsors avoid justifying costs. It is that justifying costs and justifying margin are treated as two different conversations, and only sites are expected to have both of them.

The Mission Discount

Perhaps most insidious is the cultural pressure applied through the language of mission. Sites are reminded — sometimes subtly, sometimes directly — that participating in research benefits patients and advances science. This is true. But it is equally true for the pharmaceutical company sponsoring the study, and that truth does not appear anywhere in their margin calculations. The mission framing, when selectively applied only to sites, functions as a soft mechanism for suppressing financial expectations.

The Benchmark Trap

Sponsors and CROs frequently reference "industry benchmarks" when pushing back on site budgets. Those benchmarks, however, are largely derived from historical payment norms established during a period when sites had little negotiating infrastructure and even less bargaining power. Using a suppressed historical baseline to define a current "fair" rate is circular logic that perpetuates the underpayment it attempts to measure.

That context is changing. Sites are increasingly approaching budget negotiations with the same rigor the industry has long expected of them in clinical operations. Rate cards grounded in actual cost data, overhead allocation models, and documented labor costs are becoming more common tools at the negotiating table. Organizations like SCRS and ACRP have invested in education and resources that help sites understand their own financial position and advocate for it. Site networks are pooling knowledge and building negotiating infrastructure that individual sites historically lacked.

The benchmark, in other words, is no longer the only reference point in the room. As sites arrive better prepared and better informed, the pressure on historical norms will grow. The question for sponsors and CROs is whether they meet that shift with resistance or with the kind of collaborative recalibration that serves everyone's long-term interest in a functional, well-resourced site landscape.

Why This Is A Problem For All Stakeholders

The consequences of chronic site underfunding don’t remain at the site level. They ripple outward in ways that ultimately harm the sponsors and CROs who benefit most from a robust site landscape.

The underfunding problem does not just create financial strain. It creates behavioral distortion on both sides. When sites cannot recover true costs through transparent negotiation, some may compensate by inflating line items where they believe scrutiny will be lower: padding visit costs, building margin into per-procedure rates, or layering contingency into areas that are harder to benchmark. Sponsors and CROs, aware of the practice, respond with increasingly granular budget reviews designed to identify and eliminate exactly that kind of inflation. The result is a negotiation dynamic that is adversarial by design: Sites obscure where they need margin, and sponsors and CROs hunt for it. Both sides spend significant time and resources on a process that produces neither trust nor accuracy. The final negotiated budget often reflects not what the trial actually costs to run well at a particular site but what each party was able to hide or extract in a given round. That is a poor foundation for a partnership that depends on transparency, data integrity, and shared commitment to the protocol.

Sites that cannot cover their true costs have three choices: absorb the loss, reduce their research activity, or exit the trial ecosystem entirely. All three outcomes reduce the pool of qualified, experienced sites available for future studies. Enrollment timelines lengthen. Protocol deviations increase when undertrained or overextended staff try to manage studies without adequate resources. Data quality suffers. Screen failure rates rise when sites cannot invest in proper patient identification and prescreening processes.

The site capacity crisis that the industry frequently discusses, such as the difficulty of finding experienced, well-staffed sites willing to take on new studies, is not unrelated to the financial pressure sites have absorbed over decades. These are not independent phenomena; financial nonviability is a direct driver of site attrition.

The Path Forward: Practical Solutions

Closing the double standard requires deliberate action from multiple directions. No single solution is sufficient, but several approaches together can shift the dynamic.

Break the inflation-interrogation cycle together

The adversarial budget dynamic will not end until sponsors and CROs create the conditions that make site budget transparency safe. That means explicitly signaling that an honest budget will be received as a professional document rather than an opening position to be dismantled. The pre-study visit is a natural moment for that signal. When a CRA or sponsor representative arrives at a site and communicates that realistic margins are expected and welcome and that the goal is a budget that actually works for both parties, it changes what happens when the site submits its numbers. Sites that have spent years absorbing cuts will not risk transparency until the behavior across the table gives them a reason to.

When budgets are presented, sponsors and CROs can reinforce that environment by engaging with documented line items on their merits rather than applying reflexive reductions. A site that submits a coordinator hourly rate with supporting cost data deserves a response to that data — not a counteroffer anchored to a historical benchmark that was itself the product of years of suppressed negotiation.

Sites, for their part, must be willing to meet that good faith with honest numbers. The cycle breaks only when both commitments hold simultaneously, with sponsors and CROs creating a safer environment and sites using it rather than testing it. Pre-negotiated rate frameworks and multi-study master agreements already exist in parts of the industry and have demonstrated real reductions in start-up time and administrative burden. Extending that model to include open, good-faith budget conversations that account for true site costs and reasonable margin is a logical and overdue next step.

Sites: Build and defend transparent cost accounting

Sites that lack rigorous internal cost data are negotiating blindly and are at a higher risk of remaining underfunded. Developing genuine overhead allocation models that capture true labor costs, infrastructure, regulatory burden, and margin transforms budget conversations from subjective debates into defensible business discussions. A site that can demonstrate what a coordinator hour actually costs, in documented and auditable form, is in a fundamentally stronger negotiating position than one that simply asks for "more." Knowing why you need more and being able to show it is a strategy. Simply asking for it is not.

Sponsors and CROs: Apply the same scrutiny symmetrically

Behavior changes on the sponsor and CRO side start before the budget template is ever presented to the sites. Clear guidance at the PSV, how a budget template is structured, and whether a site feels it has room to be honest — these are not incidental details. They are the conditions that determine what numbers come back. Sponsors and CROs that invest in creating conditions in which realistic margins are welcome rather than subject to automatic reduction will get more accurate budgets, faster negotiations, and sites that are actually resourced to perform.

Reframe sustainability as a quality metric

The most effective reframe available to the industry is also the most accurate one: Financially sustainable sites produce better research. Adequate compensation enables experienced staff retention. Appropriate infrastructure investment reduces protocol deviations. Sites that are not financially stressed have the bandwidth to invest in training, process improvement, and patient engagement. Framing site margin not as a financial preference but as a quality and risk management imperative shifts the conversation from entitlement to evidence.

That is a conversation the entire industry should be willing to have.

The clinical research industry cannot sustainably hold two incompatible beliefs: that pharmaceutical companies deserve returns on investment and that the research sites making that investment possible do not. One of those beliefs will eventually win. The question is whether it happens through deliberate reform — or through the slow attrition of the sites the industry cannot afford to lose.

About The Author:

Maria P. Ladd has been in the clinical research industry for 20+ years. She is a passionate site advocate, a site operations consultant, and cofounder of the Clinical Research Site Collective. As a key collaborator and champion of change for site engagement, Maria can be found on LinkedIn where she lends a strong voice to the clinical research community at large.